EcoDrugPlus

Solute Carrier Family 29 Member 1 (Augustine Blood Group)

Ensembl ID : ENSUAMG00000016657
Gene Symbol: SLC29A1
2 Cross references
284 Possible Orthologues:

Solute Carrier Family 5 Member 1

Ensembl ID : ENSUAMG00000017417
Gene Symbol: SLC5A1
2 Cross references
250 Possible Orthologues:

Solute Carrier Family 5 Member 2

Ensembl ID : ENSUAMG00000013983
Gene Symbol: SLC5A2
2 Cross references
197 Possible Orthologues:

Solute Carrier Family 6 Member 1

Ensembl ID : ENSUAMG00000021253
Gene Symbol: SLC6A1
2 Cross references
276 Possible Orthologues:

Solute Carrier Family 6 Member 3

Ensembl ID : ENSUAMG00000013965
Gene Symbol: SLC6A3
2 Cross references
166 Possible Orthologues:

Solute Carrier Family 6 Member 4

Ensembl ID : ENSUAMG00000019521
Gene Symbol: SLC6A4
2 Cross references
204 Possible Orthologues:

Solute Carrier Family 6 Member 9

Ensembl ID : ENSUAMG00000026463
Gene Symbol: SLC6A9
2 Cross references
207 Possible Orthologues:

Solute Carrier Family 9 Member A3

Ensembl ID : ENSUAMG00000022235
Gene Symbol: SLC9A3
2 Cross references
234 Possible Orthologues:

Somatostatin Receptor 1

Ensembl ID : ENSUAMG00000003135
Gene Symbol: SSTR1
2 Cross references
158 Possible Orthologues:

Somatostatin Receptor 2

Ensembl ID : ENSUAMG00000007618
Gene Symbol: SSTR2
2 Cross references
263 Possible Orthologues:

Somatostatin Receptor 3

Ensembl ID : ENSUAMG00000023892
Gene Symbol: SSTR3
2 Cross references
249 Possible Orthologues:

Somatostatin Receptor 4

Ensembl ID : ENSUAMG00000002519
Gene Symbol: SSTR4
2 Cross references
100 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).